Asteno neurotic syndrome in children

Active substance:


Pharmacological groups

Nosological classification (ICD-10)

3D images

Description of the dosage form

Capsules, 25 mg: solid gelatin, size No. 3, white.

Capsules, 50 mg: solid gelatin, size No. 3, body in white, blue cap.

Capsules, 125 mg: hard gelatin, size No. 2, body in white, blue cap.

Capsules, 250 mg: solid gelatinous, size No. 0, body in white, lid in dark blue.

Capsule contents: a mixture of powder and / or granules of white or white with a yellowish tinge.

pharmachologic effect


Nootropic agent, facilitates GABA-mediated transmission of nerve impulses to the central nervous system (direct effect on GABAergic receptors). The tranquilizing effect is combined with an activating effect. Also has antiplatelet, antioxidant and some anticonvulsant action.

Improves the functional state of the brain due to the normalization of its metabolism and the effect on cerebral blood flow (increases volumetric and linear speed, reduces the resistance of blood vessels, improves microcirculation, has antiaggregant effect). Lengthens the latent period and shortens the duration and severity of nystagmus.

It does not affect the cholino and adrenoreceptors. Reduces vasovegetative symptoms (in

Reduces the manifestations of asthenia (improves health, increases interest and initiative – the motivation of activity) without sedation or excitement.

It helps to reduce feelings of anxiety, tension and anxiety, normalizes sleep.

In older people does not cause depression of the central nervous system, muscular-relaxing aftereffect is most often absent.


Absorption is high, penetrates well into all tissues of the body and through the BBB (about 0.1% of the administered dose of the drug penetrates into the brain tissue, and in young and old people to a much greater extent). Evenly distributed in the liver and kidneys.

Metabolized in the liver – 80–95%, metabolites are pharmacologically inactive. Not cumulated. After 3 h, it begins to be excreted by the kidneys, while the concentration in the brain tissue does not decrease and is found for an additional 6 hours. About 5% is excreted by the kidneys unchanged, partially with bile.

Indications for Anvifen ®

asthenic and anxiety-neurotic states;

stuttering, tics and enuresis in children;

insomnia and nighttime anxiety in the elderly;

Meniere’s disease, dizziness associated with dysfunction of the vestibular analyzer of various origins;

prevention of motion sickness with kinetozakh;

in the complex therapy of alcohol withdrawal syndrome for the relief of psychopathological and somatovegetative disorders.


breastfeeding period;

age up to 3 years.

With care: erosive and ulcerative lesions of the gastrointestinal tract; liver failure.

Side effects

Drowsiness, nausea, irritability, agitation, anxiety, dizziness, headache (at the first reception), allergic reactions.


Extends and enhances the effect of hypnotic drugs, narcotic analgesics, antipsychotics, anti-Parkinsonian and antiepileptic drugs.

Asteno neurotic syndrome in children

Dosage and administration

Inside, after meals, 2-3 week courses.

Adults and children from 14 years old – 250–500 mg 3 times a day (maximum daily dose – 2500 mg). Children 3–8 years old – 50–100 mg 3 times a day; 8-14 years – 250 mg 3 times a day.

A single maximum dose in adults and children from 14 years old is 750 mg, in persons over 60 years old – 500 mg, for children under 8 years old – 150 mg, from 8 to 14 years old – 250 mg.

Alcohol withdrawal syndrome: 250-500 mg 3 times a day and at night 750 mg, with a gradual decrease in the daily dose to the usual for adults.

Treatment of dizziness with dysfunctions of the vestibular apparatus and Meniere’s disease: 250 mg 3 times a day for 14 days.

Prevention of motion sickness: 250–500 mg once, 1 hour before the expected start of rolling or when the first symptoms of seasickness appear.

Counter-pumping effect of the drug ANVIFEN ® increases with increasing dose of the drug. With the onset of pronounced manifestations of seasickness (vomiting and


Symptoms: severe drowsiness, nausea, vomiting, fatty liver (taking more than 7 g), eosinophilia, decreased blood pressure, renal dysfunction.

Treatment: gastric lavage, the appointment of activated charcoal and symptomatic therapy.

special instructions

With prolonged use, it is necessary to periodically monitor the performance of the liver and peripheral blood.

Influence on ability to steer vehicles and work with mechanisms. It is necessary to refrain from potentially hazardous activities that require increased concentration.

Release form

Capsules, 25 mg, 50 mg, 125 mg, 250 mg. 10 caps. in blister strip packaging. 1, 2, 3 or 5 blister packs in a carton box.

Asteno neurotic syndrome in children


JSC “Farmproekt”. 192236, St. Petersburg, ul. Sofia, 14, lit. BUT.

Tel / Fax: (812) 331-93-10.

The name and address of the legal entity in whose name the registration certificate / organization has been issued receives claims: LLC Anvilab. 141302, Russia, Moscow region, Sergiev-Posad municipal district, city settlement Sergiev Posad, Sergiev Posad, ul. Festival, 10.

Tel / Fax: (495) 921-43-42.

Pharmacy sales terms

Storage conditions of the drug Anvifen ®

Keep out of the reach of children.

The shelf life of the drug Anvifen ®

Do not use after the expiration date printed on the package.

Like this post? Please share to your friends:
Leave a Reply